Extended Data Fig. 5: The reported (black) and adjusted (red) seroprevalence.
From: Burden and characteristics of COVID-19 in the United States during 2020
(a) Results for the 10-site study. (b) and (c) show the results for state-level serological surveys obtained using a maximum monthly attenuation rate of 17.5% and 15%, respectively. Dots and whiskers show the median and 95% CIs respectively. Distributions are obtained from n = 1,000 simulated seroprevalence samples.
